These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 7930274)

  • 21. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial.
    Antman EM
    Circulation; 1996 Sep; 94(5):911-21. PubMed ID: 8790025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.
    GUSTO investigators
    N Engl J Med; 1993 Sep; 329(10):673-82. PubMed ID: 8204123
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized trial of intravenous heparin in conjunction with anistreplase (anisoylated plasminogen streptokinase activator complex) in acute myocardial infarction: the Duke University Clinical Cardiology Study (DUCCS) 1.
    O'Connor CM; Meese R; Carney R; Smith J; Conn E; Burks J; Hartman C; Roark S; Shadoff N; Heard M
    J Am Coll Cardiol; 1994 Jan; 23(1):11-8. PubMed ID: 8277068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fatal cardiac rupture among patients treated with thrombolytic agents and adjunctive thrombin antagonists: observations from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction 9 Study.
    Becker RC; Hochman JS; Cannon CP; Spencer FA; Ball SP; Rizzo MJ; Antman EM
    J Am Coll Cardiol; 1999 Feb; 33(2):479-87. PubMed ID: 9973029
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The absence of a procoagulant effect after TNK-t-PA: a comparison with streptokinase and rt-PA].
    De Marco E; Andreotti F; van de Greef W; Quaranta G; Biasucci LM; Kol A; Maseri A; Rebuzzi AG
    Cardiologia; 1998 Nov; 43(11):1209-13. PubMed ID: 9922587
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence on coagulation activity by subcutaneous LMW heparin as an adjuvant treatment to fibrinolysis in acute myocardial infarction.
    Frostfeldt G; Gustavsson G; Lindahl B; Nygren A; Siegbahn A; Wallentin L
    Thromb Res; 2002 Feb; 105(3):193-9. PubMed ID: 11927123
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multicenter reperfusion trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: controlled comparison with intracoronary streptokinase.
    Anderson JL; Rothbard RL; Hackworthy RA; Sorensen SG; Fitzpatrick PG; Dahl CF; Hagan AD; Browne KF; Symkoviak GP; Menlove RL
    J Am Coll Cardiol; 1988 Jun; 11(6):1153-63. PubMed ID: 3284943
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial.
    Cannon CP; McCabe CH; Henry TD; Schweiger MJ; Gibson RS; Mueller HS; Becker RC; Kleiman NS; Haugland JM; Anderson JL
    J Am Coll Cardiol; 1994 Apr; 23(5):993-1003. PubMed ID: 8144799
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Streptokinase-induced hypotension has no detrimental effect on patients with thrombolytic treatment for acute myocardial infarction. A substudy of the Romanian Study for Accelerated Streptokinase in Acute Myocardial Infarction (ASK-ROMANIA).
    Tatu-Chiţoiu G; Teodorescu C; Dan M; Guran M; Căpraru P; Istrăţescu O; Tatu-Chiţoiu A; Bumbu A; Chioncel V; Arvanitopol S; Dorobanţu M
    Rom J Intern Med; 2004; 42(3):557-73. PubMed ID: 16366130
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators.
    Metz BK; White HD; Granger CB; Simes RJ; Armstrong PW; Hirsh J; Fuster V; MacAulay CM; Califf RM; Topol EJ
    J Am Coll Cardiol; 1998 Jun; 31(7):1493-8. PubMed ID: 9626825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction--a pilot study: biochemical markers in acute coronary syndromes (BIOMACS II).
    Frostfeldt G; Ahlberg G; Gustafsson G; Helmius G; Lindahl B; Nygren A; Siegbahn A; Swahn E; Venge P; Wallentin L
    J Am Coll Cardiol; 1999 Mar; 33(3):627-33. PubMed ID: 10080461
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris.
    Gold HK; Torres FW; Garabedian HD; Werner W; Jang IK; Khan A; Hagstrom JN; Yasuda T; Leinbach RC; Newell JB
    J Am Coll Cardiol; 1993 Apr; 21(5):1039-47. PubMed ID: 8459055
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efegatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infarction. ESCALAT Investigators.
    Fung AY; Lorch G; Cambier PA; Hansen D; Titus BG; Martin JS; Lee JJ; Every NR; Hallstrom AP; Stock-Novack D; Scherer J; Weaver WD
    Am Heart J; 1999 Oct; 138(4 Pt 1):696-704. PubMed ID: 10502216
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Subcutaneous enoxaparin following thrombolysis and intravenous unfractionated heparin in ST-elevation acute myocardial infarction: safety and efficacy of low vs full dose.
    Rubboli A; Gatti C; Spinolo L; Parollo R; Spitali G; Maresta A
    Minerva Cardioangiol; 2006 Feb; 54(1):131-7. PubMed ID: 16467747
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of heparin on fibrinogen and D-dimer plasma levels in acute myocardial infarction treated with streptokinase.
    Salvioni A; Marenzi GC; Agostoni P; Grazi S; Guazzi MD
    Eur Heart J; 1994 May; 15(5):654-9. PubMed ID: 8056006
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Bolus injection of anisoylated plasminogen-streptokinase activator complex (BRL 26921) as an alternative concept of systemic lysis in acute myocardial infarct].
    Doenecke P; Schwerdt H; Hellstern P; Wenzel E; Bette L
    Klin Wochenschr; 1986 Aug; 64(15):682-7. PubMed ID: 3531704
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: the COMPASS Equivalence Trial. Comparison Trial of Saruplase and Streptokinase (COMASS) Investigators.
    Tebbe U; Michels R; Adgey J; Boland J; Caspi A; Charbonnier B; Windeler J; Barth H; Groves R; Hopkins GR; Fennell W; Betriu A; Ruda M; Mlczoch J
    J Am Coll Cardiol; 1998 Mar; 31(3):487-93. PubMed ID: 9502624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Accelerated infusion of streptokinase in acute myocardial infarction results in better TIMI flow grade in infarct-related artery.
    Dwivedi SK; Saran RK; Narain VS; Bansal S; Gupta R; Puri VK
    Indian Heart J; 2000; 52(1):40-4. PubMed ID: 10820932
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Aspirin and heparin in the fibrinolytic treatment of acute myocardial infarction].
    López Bescós L
    Rev Esp Cardiol; 1992; 45 Suppl 2():21-8. PubMed ID: 1475505
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of heparin in coronary thrombolysis.
    Eisenberg PR
    Chest; 1992 Apr; 101(4 Suppl):131S-139S. PubMed ID: 1555478
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.